Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Interleukin-6 Receptors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Interleukin-6 Receptors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Interleukin-6 (IL-6) is a multifunctional cytokine that plays a crucial role in the immune system and inflammation. It exerts its effects through binding to its specific cell-surface receptors, IL-6 receptors (IL-6Rs), which trigger a signaling cascade within the cell. Upon binding to IL-6 receptors, the receptor complex undergoes a series of conformational changes, leading to the activation of intracellular signaling pathways, particularly the JAK-STAT pathway. This activation induces the expression of various genes involved in immune responses and inflammation, thereby modulating the body's immune system and promoting immune reactions against infections or tissue damage. IL-6 plays a crucial role in the body as a multifunctional cytokine. It is involved in regulating immune responses, inflammation, and hematopoiesis. Additionally, IL-6 influences the liver's acute-phase response, stimulates the production of antibodies, and supports the differentiation of various immune cells, making it a key player in maintaining immune homeostasis. IL-6/IL-6 receptor signaling plays a vital role in multiple diseases, and targeting this pathway has become a therapeutic approach in medicine. For instance, in rheumatoid arthritis, IL-6 inhibitors have shown significant efficacy in reducing inflammation and joint damage. Additionally, IL-6/IL-6R antagonists have been utilized to treat certain types of cytokine release syndrome, a severe immune reaction observed in some cancer immunotherapies. Furthermore, they have been investigated in conditions like inflammatory bowel disease, systemic juvenile idiopathic arthritis, and certain cancers, as they can modulate inflammatory processes and immune responses. Extensive research is being conducted to find new and novel molecules to prevent and cure these diseases. The development and launch of more recent products by the market players will significantly enhance the revenue of the IL-6/IL-6 Receptors market over the forecast years.
A number of these inhibitors are in the market, while many are in ongoing clinical trials. Companies in their pipelines have 112 products in various stages of clinical trials. 9 products in Phase 4, 18 products in Phase 3, 14 products in Phase 2, and 4 products are in Phase 1 of the clinical trials.
Key Developments of IL-6/IL-6 Receptors
Approved molecules
Drugs in Pipeline
Clinical Activity and Developments of IL-6/IL-6 Receptors
As of July 2023, 112 products for 727 diseases are in clinical trials. For instance,
|
Molecule name |
Number of studies |
|
Actemra IV (tocilizumab) |
502 |
|
Actemra SC (tocilizumab SC) |
64 |
|
Kevzara (sarilumab) |
62 |
|
Rizaben (tranilast) |
15 |
|
Amzeeq (minocycline topical foam 4%) |
12 |
IL-6/IL-6 receptor targeting agents have found significant use in various clinical indications, particularly in the management of inflammatory and autoimmune disorders. Rheumatoid arthritis is one of the most prominent indications, where IL-6 inhibitors have demonstrated substantial efficacy in reducing inflammation and preventing joint damage. In addition, these agents have been employed in treating other autoimmune conditions, such as systemic juvenile idiopathic arthritis and inflammatory bowel disease, where IL-6 plays a critical role in the pathogenesis of these diseases. Moreover, they have shown promise in addressing certain types of cytokine release syndrome, a severe immune reaction observed in cancer immunotherapies. Ongoing research explores their potential application in other inflammatory conditions and cancers, underscoring the wide-ranging therapeutic value of targeting the IL-6/IL-6 receptor pathway.
The global net sales of Actemra by Roche were $2,952.19 million in the financial year 2022, which was 22% less than the sales in 2021, being $3,893.26 million. The net revenue earned by Regeneron Pharmaceuticals from Kevzara was $199.7 million in the USA while $158.3 million from the rest of the world. The net revenue rose 6% as compared to the sales in 2021, which was $161.9 million from the USA and $176.1 million from the rest of the world. However, the net revenue of Kevzara from the three months ended December 2022 saw a sharp decline of 22% in sales compared to the sales in 2021. According to a 2020 study, the global prevalence of rheumatoid arthritis is about 1% but varies by geography and latitude in Europe. Countries such as Sweden and Germany had prevalence rates of 0.65 percent, while France and Italy had a lower prevalence than global estimates of 0.19 percent and 0.41 percent, respectively. Variation in prevalence rates is also influenced by several factors, such as gender and environmental factors.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Actemra SC (tocilizumab SC), Kevzara (sarilumab), Rizaben (tranilast), and Amzeeq (minocycline topical foam 4%) are approved by the FDA.
These are being used in various indications like Rheumatoid Arthritis, Connective tissue diseases, Vascular diseases, and others.
Roche, JW Pharma, Halozyme Therapeutics, Asahi Kasei Pharma Corporation, Regeneron Pharmaceuticals, and Sanofi are major market players for IL-6/IL-6 Receptors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to different types of disorders like Rheumatoid Arthritis, Skin, and connective tissue diseases are the key opportunities for IL-6/IL-6 Receptors in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.